Applications of 4-Androsten-3-One-5-Ene-17-Carboxylic Acid in Industrial Manufacturing

As an established manufacturer, we provide 4-Androsten-3-One-5-Ene-17-Carboxylic Acid with strict process control for industries where steroid intermediates are critical starting materials. This compound serves as a backbone for synthesizing several regulated bioactive molecules. The following application fields reflect actual downstream adoption in major chemical and pharmaceutical manufacturing operations.

1. Active Pharmaceutical Ingredient (API) Synthesis – Corticosteroid Intermediates

Corticosteroid manufacturers use this compound as a core intermediate in the multistep production of hydrocortisone and its derivatives. Synthetic pathways build on its androstene skeleton to introduce functional groups required for endocrine therapies. Careful control of residual purity ensures downstream process efficiency and regulatory compliance at every stage.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• USP, EP, and JP monographs for corticosteroid APIs
• FDA 21 CFR Part 211 current Good Manufacturing Practice
• EDQM Certificate of Suitability for intermediates

Typical usage ratio

• 0.8–1.2 molar equivalents relative to target corticosteroid, based on stepwise synthesis yield targets

Downstream process integration

• Utilized during early-stage side-chain modifications and ring oxidation steps in multistep batch synthesis of steroidal APIs
• Introduced into closed hydrogenation or oxidation reactors with controlled release protocols to prevent cross-contamination

Final product types

• Hydrocortisone and hydrocortisone acetate bulk drug substances
• Cortisone and related medicinal corticosteroids for finished dosage forms
• Pharmaceutical-grade intermediates supplied to global API formulators

2. Veterinary Pharmaceutical Manufacturing – Glucocorticoid Formulation Intermediate

Veterinary pharmaceutical plants rely on this raw material to construct glucocorticoid molecules essential for anti-inflammatory and immunosuppressive animal health products. Its controlled conversion preserves the stereochemistry necessary for consistent animal drug performance, achieved with robust in-process analytical checks.

Industry compliance standards

• European Pharmacopoeia (EP) veterinary substance monographs
• US FDA CVM guidance for veterinary drugs
• VICH GL guidelines on control of starting materials
• ISO 9001:2015 for veterinary active pharmaceutical intermediates

Typical usage ratio

• Set at 1.0 molar equivalent, tuned within ±5% according to animal species-specific formulation scales and batch yield

Downstream process integration

• Introduced into ring functionalization and hydroxylation steps for synthesis of veterinary glucocorticoids
• Monitored with online HPLC for residue tracking in continuous processing lines

Final product types

• Prednisolone and methylprednisolone veterinary finished APIs
• Steroidal veterinary injectables, oral suspensions, and premix powders

3. Custom Steroidal Intermediate Production for Contract Development Organizations (CDMOs)

Custom synthesis providers and CDMOs incorporate this carboxylic acid as a platform molecule for project-based manufacture of novel steroid intermediates. Its chemical structure supports variant side-chain installation, enabling tailored downstream synthesis for proprietary forms requested under contract development for specialty drugs.

Industry compliance standards

• FDA 21 CFR Part 210/211 GMP for pharmaceutical manufacturing
• Customer-specific quality agreements incorporating ICH Q11 guidance
• Controlled Substance Act compliance as required for regulated derivatives
• ALCOA+ principles for data integrity in custom API programs

Typical usage ratio

• Ranges from 0.9 to 1.5 equivalents, optimized per custom project protocol and reactant stoichiometry

Downstream process integration

• Charged as a foundational reactant in pilot and clinical batch reactors at stage one of target intermediate synthesis
• Paired with advanced process analytical technology for real-time control of chemical transformation

Final product types

• Novel steroid intermediates for NCE (New Chemical Entity) development pipelines
• Building blocks for early-stage clinical trial pharmaceuticals
• Custom intermediates for international CDMO partner supply chains

4. Fine Chemical Feedstock for Analytical Reference Materials

Producers of certified analytical standards utilize our material as a high-purity feedstock to prepare steroid reference substances. These high-grade materials anchor quality control routines in pharmaceutical and forensic analysis, requiring traceable batch records and exacting impurity profiles.

Industry compliance standards

• ISO 17034 requirements for reference material producers
• ISO/IEC 17025 standards for testing and calibration laboratories
• USP Reference Standard certification protocols
• Pharmaceutical and forensic laboratory accreditation requirements

Typical usage ratio

• Between 97–99% purity content in the final standard, with addition rates calculated based on target mass for each calibrator batch

Downstream process integration

• Charged to purification columns and crystallization units to deliver homogenous lots for analytical reference production
• Subjected to final identity and purity verification using NMR and LC-MS before packaging

Final product types

• Certified steroid reference standards and calibration solutions
• Traceable quality control materials for pharmaceutical release testing
• Chemical reference libraries for academic and regulatory laboratories

5. API Intermediate for Hormone Replacement Therapy Ingredients

Hormone therapy ingredient manufacturers utilize this raw material in synthetic schemes for key intermediates of androgen or progestogen hormone drugs. Its structural properties enable efficient conversion into bio-identical intermediates, supported by tight impurity control and validated scale-up data at kilogram-to-ton production scales.

Industry compliance standards

• FDA Drug Master File submissions (DMF Type II)
• Good Manufacturing Practice (GMP) EU EudraLex, Volume 4
• Chinese Pharmacopoeia requirements for hormone substances
• WHO Technical Report Series for hormone intermediates

Typical usage ratio

• 800–1200 grams per kg of target HRT intermediate, adjusted based on stereochemical pathway efficiency and impurity limits

Downstream process integration

• Loaded at the controlled addition stage during initial ring closure or functionalization reactors
• Passed through in-situ QC checkpoints to assure intermediate quality for hormone synthesis

Final product types

• Androgen and progestogen intermediates for hormone replacement therapies
• Pharmaceutical-grade hormone APIs for oral and injectable preparations